DOP Session 8

DOP64-72

  • 17:05-18:05 Digital Oral Presentation Session 8: Intestinal healing
    Room: C1-M2, Hall C, Bella Center
    Chairs: Raja Atreya, Erlangen, Germany
    Marietta Iacucci, Birmingham, United Kingdom
      17:05-17:11 DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with Inflammatory Bowel Disease
    See Presentation Slides here
    L.-Y. Mak1, L. Chen2, T. Tong2, S. Lau2, W.-K. Leung2
    1
    Queen Mary Hospital, Medicine, Hong Kong, Hong Kong, 2The University of Hong Kong, Medicine, Hong Kong, Hong Kong
      17:11-17:17 DOP65: The association of faecal calprotectin level and combined mucosal and transmural healing in patients with Crohn's Disease
    See Presentation Slides here
    S. Noh1, E. H. Oh1, S. H. Park2, 3, J. B. Lee4, J. Y. Kim1, J. C. Park1, J. Kim1, N. Ham1, E. M. Song1, S. H. Park1, 3, S. W. Hwang1, 3, D. H. Yang1, J. S. Byeon1, S. J. Myung1, S. K. Yang1, 3, B. D. Ye1, 3
    1
    Asan medical center, Gastroenterology, Seoul, South Korea, 2Asan medical center, Radiology, Seoul, South Korea, 3Asan medical center, Inflammatory Bowel Disease Center, Seoul, South Korea, 4Asan medical center, Clinical Epidemiology & Biostatistics, Seoul, South Korea
      17:17-17:23 DOP66: Surveillance colonoscopies in Ulcerative Colitis: Does it make a difference?
    See Presentation Slides here
    A. Hu1, G. Nguyen2, J. Rangrej3, J. Marshall1, N. Narula1
    1
    McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, Canada, 2University of Toronto, Division of Gastroenterology, Mount Sinai Hospital, Toronto, Canada, 3Ministry of Health and Long-Term Care, Health Analytics Branch, Toronto, Canada
      17:23-17:29 DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histologic inflammation in patients with Inflammatory Bowel Disease
    See Presentation Slides here
    E. Klenske1, R. Atreya1, A. Hartmann2, S. Fischer1, S. Hirschmann1, S. Zundler1, M. Iacucci3, M. Neurath1, T. Rath1
    1
    University Hospital of Erlangen, Department of Medicine 1, Division of Gastroenterology, Erlangen, Germany, 2University Hospital of Erlangen, Institute of Pathology, Erlangen, Germany, 3University of Birmingham, Institute of Translational Medicine, Birmingham, United Kingdom
      17:29-17:35 DOP68: Histological remission (NANCY index) is superior to endoscopic mucosal healing in predicting relapse free survival in patients with Ulcerative Colitis in clinical and endoscopic remission
    H. Wang1, I. Fewings2, L. Bornman1, B. Shadbolt3, M. Fadia2, K. Subramaniam1, 4
    1
    Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia, 2ACT Pathology, Canberra Hospital, Canberra, Australia, 3Health Analytics Research Centre, Canberra Hospital, Canberra, Australia, 4ANU Medical School, Australian National University, Canberra, Australia
      17:35-17:41 DOP69: The detection with targeted biopsy and characterisation of neoplastic lesions by magnifying chromoendoscopy and NBI in surveillance colonoscopy of patients with Ulcerative Colitis: A sub-analysis of the Navigator Study
    K. Watanabe1,2, M. Esaki3, S. Oka4, F. Shimamoto5, M. Nishishita2, T. Fukuchi6, S. Fujii7, F. Hirai8, K. Kakimoto9, T. Inoue9, H. Kashida10, K. Takeuchi11, N. Ohmiya12, M. Saruta13, S. Saito14, Y. Saito15, S. Tanaka16, Y. Ajioka17, H. Tajiri13
    1
    Hyogo College of Medicine, Intestinal Inflammation Research, Nishinomiya, Japan, 2Nishishita GI Hospital, Osaka, Japan, 3Saga University, Saga, Japan, 4Hiroshima University, Hiroshima, Jamaica, 5Prefectural University of Hiroshima, Hiroshima, Japan, 6Osakafu Saiseikai Nakatsu Hospital, Osaka, Japan, 7Kyoto Katsura Hospital, Kyoto, Japan, 8Fukuoka University Chikushi Hospital, Fukuoka, Japan, 9Osaka Medical College, Osaka, Japan, 10Kinki University, Osaka, Japan, 11Toho University Sakura Medical Center, Chiba, Japan, 12Fujita Medical University, Aichi, Japan, 13The Jikei University School of Medicine, Tokyo, Japan, 14The Cancer Institute Hospital Of JFCR, Tokyo, Japan, 15National Cancer Center Hospital, Tokyo, Japan, 16Hiroshima University, Hiroshima, Japan, 17Niigata University, Niigata, Japan
      17:41-17:47 DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's Disease
    See Presentation Slides here
    B. Verstockt1,2, P. Sudahakar2, 3, 4, B. Creyns5, S. Verstockt6, J. Cremer5, W.-J. Wollants2, S. Organe2, T. Korcsmaros3, 4, M. Madgwick3, G. Van Assche1, 2, C. Breynaert5, S. Vermeire1, 2, M. Ferrante1, 2
    1
    University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3Earlham Institute, Norwich, United Kingdom, 4Quadram Institute, Norwich, Belgium, 5KU Leuven, Department of Microbiology and Immunology, Laboratory of Clinical Immunology, Leuven, Belgium, 6KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium
      17:47-17:53 DOP71: Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in Ulcerative Colitis
    See Presentation Slides here
    K. Li1, J. R. Friedman1, C. Marano1, H. Zhang1, F. Yang1, B. G. Feagan2, L. Peyrin-Biroulet3, G. De Hertogh4
    1
    Janssen Research & Development, LLC, Spring House, United States, 2Robarts Research Institute, Robarts Clinical Trials, London, Canada, 3Nancy University Hospital, Université de Lorraine, Nancy, France, 4University Hospitals KU, Leuven, Belgium
      17:53-17:59 DOP72: Increased risk of advanced neoplasia in Inflammatory Bowel Disease patients with recurrent low-grade dysplasia
    See Presentation Slides here
    M. de Jong1, H. Kanne1, L. Nissen2, I. Nagtegaal3, J. Drenth1, L. Derikx1, 2, F. Hoentjen1
    1
    Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, Netherlands, 2Jeroen Bosch Hospital, Gastroenterology and Hepatology, s'Hertogenbosch, Netherlands, 3Radboud University Medical Center, Pathology, Nijmegen, Netherlands

Digital Oral Presentations
(as of January 2019)

  • DOP Session 1 Advances in IBD pathophysiology
    DOP01-09
    Room: C1 M1
    Chairs: Javier Gisbert, Madrid, Spain
    Maximilian Waldner, Erlangen, Germany
    DOP Session 2 Mechanisms of intestinal inflammation
    DOP10-18
    Room: C1 M0
    Chairs: Loris Riccardo Lopetuso, Rome, Italy
    Britta Siegmund, Berlin, Germany
    DOP Session 3 Translational science in IBD
    DOP19-27
    Room: C1 M2
    Chairs: Peter Bossuyt, Bonheiden, Belgium
    Axel Dignass, Frankfurt, Germany
    DOP Session 4 Practicalities of IBD patient care
    DOP28-36
    Room: C1 M3
    Chairs: Uri Kopylov, Tel Aviv, Israel
    Fernando Magro, Porto, Portugal
    DOP Session 5 Old and new treatment
    DOP37-45
    Room: C1 M4-5
    Chairs: Paolo Gionchetti, Bologna, Italy
    Anne Strik, Amsterdam, The Netherlands
  • DOP Session 6 Novel treatments
    DOP46-54
    Room C1 M4-5
    Chairs: Marc Ferrante, Leuven, Belgium
    Gionata Fiorino, Rome, Italy
    DOP Session 7 Recent advances of biologic therapies
    DOP55-63
    Room: C1 M3
    Chairs: Filip Baert, Roeselare, Belgium
    Shomron Ben-Horin, Ramat Gan, Israel
    DOP Session 8 Intestinal healing
    DOP64-72
    Room: C1 M2
    Chairs: Raja Atreya, Erlangen, Germany
    Marietta Iacucci, Birmingham, United Kingdom
    DOP Session 9 Surgery and IBD
    DOP73-81
    Room: C1 M1
    Chairs: Paulo Kotze, Curitiba, Brazil
    Andre D'Hoore, Leuven, Belgium
    DOP Session 10 Clinical epidemiology
    DOP82-90
    Room: C1 M0
    Chairs: Stefanos Bonovas, Milan, Italy
    Johan Burisch, Copenhagen, Denmark